Phase II Trial of Palbociclib in Cancers with CCND Amplifications Shows Potential Targeted Treatment
The MATCH-Subprotocol Z1B trial is evaluating palbociclib's efficacy in cancers with CCND1, 2, or 3 amplifications.
Therapeutic Area
Therapeutic area intelligence for CDK Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.